Table 2 Ongoing clinical trials of pancreatic cancer vaccines
From: Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine
Vaccine type | NCT number | Immunogen | Additional treatment | Phase | Estimated enrollment | Status | Start point |
|---|---|---|---|---|---|---|---|
Cell-based vaccines | NCT00389610 | GVAX | No | Phase II | 56 | Active, not recruiting | 2006 |
NCT01088789 | GVAX | Cyclophosphamide | Phase II | 72 | Recruiting | 2010 | |
NCT01595321 | GVAX | SBRT, FOLFIRINOX, cyclophosphamide | Not applicable | 19 | Active, not recruiting | 2012 | |
NCT02451982 | GVAX | Cyclophosphamide | Phase II | 76 | Recruiting | 2016 | |
NCT02648282 | GVAX | Cyclophosphamide, pembrolizumab, SBRT | Phase II | 58 | Active, not recruiting | 2016 | |
NCT03190265 | GVAX | Cyclophosphamide, nivolumab, CRS-207, ipilimumab | Phase II | 63 | Active, not recruiting | 2017 | |
NCT03161379 | GVAX | SBRT, nivolumab, cyclophosphamide | Phase II | 30 | Active, not recruiting | 2018 | |
NCT03592888 | Autologous DC pulsed with mutant KRAS peptides | No | Phase I | 12 | Recruiting | 2018 | |
NCT03006302 | GVAX | Epacadostat, pembrolizumab, CRS-207, cyclophosphamide | Phase II | 40 | Active, not recruiting | 2018 | |
NCT03153410 | GVAX | Cyclophosphamide, pembrolizuma, IMC-CS4 | Phase I | 12 | Active, not recruiting | 2018 | |
NCT03767582 | GVAX | SBRT, nivolumab, CCR2/CCR5 dual antagonist | Phase I/II | 30 | Recruiting | 2019 | |
NCT04157127 | Autologous DC loaded with tumor lysate plus mRNA | No | Phase I | 43 | Recruiting | 2020 | |
NCT04627246 | Autologous DC loaded with personalized peptides | Nivolumab, chemotherapy | Phase I | 12 | Recruiting | 2020 | |
Peptide-based vaccines | NCT03558945 | Personalized neoantigen | Poly-ICLC | Phase I | 60 | Recruiting | 2018 |
NCT04161755 | Personalized neoantigen | Atezolizumab, surgery, FOLFIRINOX | Phase I | 29 | Active, not recruiting | 2019 | |
NCT04117087 | KRAS | Nivolumab, ipilimumab | Phase I | 30 | Recruiting | 2020 | |
NCT03956056 | Personalized neoantigen and mesothelin | Poly-ICLC | Phase I | 12 | Active, not recruiting | 2020 | |
NCT04810910 | Personalized neoantigen | Surgery, chemotherapy | Phase I | 20 | Recruiting | 2021 | |
NCT05111353 | Neoantigen synthetic long peptide | Poly-ICLC | Phase I | 30 | Not yet recruiting | 2022 | |
NCT05013216 | KRAS | Poly-ICLC | Phase I | 25 | Recruiting | 2022 | |
Microorganism-based vaccines | NCT00669734 | Vaccinia, fowlpox | GM-CSF | Phase I | 18 | Active, not recruiting | 2010 |
NCT03136406 | Recombinant saccharomyces cerevisiae yeast expressing mutant Ras | Cyclophosphamide, oxaliplatin, GI-4000, capecitabine, 5-fluorouracil, leucovorin, nab-paclitaxel, aNK, bevacizumab, avelumab, ALT-803, ETBX-011 | Phase I/II | 3 | Active, not recruiting | 2017 | |
NCT05116917 | Influenza virus | Nivolumab, ipilimumab, SBRT | Phase II | 30 | Recruiting | 2021 | |
DNA-based vaccines | NCT03122106 | Personalized neoantigens and mesothelin DNA | No | Phase I | 15 | Active, not recruiting | 2018 |